Table 2.
Comparison of CNS symptoms between EGFR mutated-type and EGFR wild-type patients with brain metastases.
| Author | Type of BM | EGFR MT | EGFR WT | p-Value |
|---|---|---|---|---|
| Akimasa Sekine, 2012 (66) | SC | 7.7% (2/26) | 25.8% (8/31) | 0.073 |
| Toshihiko Iuchi, 2015 (11) | SC | 31.0% (18/58) | 35.4% (34/96) | 0.577 |
| Takahiro Ando, 2018 (67) | SC | 19.0% (4/21) | 50.0% (7/14) | 0.049 |
| Xiaoyan Ma, 2016 (24) | MC | 82.4% (28/34) | – | – |
| Min Young Baek, 2018 (9) | SC+MC | 51.9% (14/27) | 57.5% (23/40) | 0.803 |
“SC+MC” means the BMs developed from diagnosis of NSCLC to death.
SC, synchronous; MC, metachronous; MT, mutated type; WT, wild type; CNS, central nervous system; EGFR, epidermal growth factor receptor; BM, brain metastasis.